Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccination timing after rituximab-CHOP in lymphoma patients
NL-OMON23415Not yet recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of influenza vaccine, rituximab and cyclophosphamide + doxorubicin + vincristine + prednisone in influenza (3 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Primary immune response endpoint. Planned start Sep 2012; status: not yet recruiting.
02
Drugs
influenza vaccinerituximabcyclophosphamide + doxorubicin + vincristine + prednisone
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON23415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23415.